

Fax

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46205  
U.S.A.

*Lilly*  
**RECEIVED**  
**CENTRAL FAX CENTER**

NOV 25 2003

To: Christine J. Saoud

OFFICIAL

Company: USPTO  
Fax: (703) ~~398-4628~~  
872-9307  
Date: November 25, 2003

From: Greg Cox  
Fax: (317) 276-3851  
Phone: (317) 277-2620  
Total Pages: 5

RE: Serial No.: 09/834,229  
Our Docket No.: X-10822A

Please see the attached revised Terminal Disclaimer and Response after Final Rejection. Please let me know if you have any questions.

Thank you,

Greg Cox  
Attorney for Applicant  
Registration No. 47,504

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

**RECEIVED  
CENTRAL FAX CENTER**

NOV 25 2003

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>K.S. Rhoades</u> Type or print name of person signing certification	
<u>K.S. Rhoades</u> Signature	<u>11-25-03</u> Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants	:	Suad Efendic	)	
Serial No.	:	09/834,229	)	
Filed	:	April 12, 2001	)	Group Art Unit:
For	:	Use of GLP-1 or Analogs in treatment of myocardial infarction	)	1647
Docket No.	:	X-10822A	)	Examiner
			)	C. Saoud

**RESPONSE AFTER FINAL REJECTION AND AMENDMENT**

**UNDER 37 C.F.R. 1.116**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Introductory Comments**

This paper is filed in response to the Examiner's final rejection of Claims 13-19, and 22-25 currently pending in the Application. Applicant respectfully requests that the Examiner enter the following terminal disclaimer that Applicant believes place the application in condition for allowance.

Please withdrawal the defective terminal disclaimer that was filed on September 9, 2003, and replace the defective terminal disclaimer with the present terminal disclaimer.

Serial No. 09/834,229

**Double Patenting**

The Examiner rejected Claims 13-19, and 22-25 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 -19 of U.S. Patent No. 6,277,819. Applicant filed a defective terminal disclaimer on September 9, 2003, which inadvertently disclaimer an unrelated patent. Please withdrawal the defective terminal disclaimer and enter the accompanying terminal disclaimer.

Applicant respectfully asserts that the Examiner's double patenting rejection has now been overcome and that the application is now in condition for allowance. If, for any reason, the Examiner feels that a telephone conversation would be helpful in expediting the prosecution of this case, the Examiner is urged to call me.

Respectfully submitted,



Gregory A. Cox  
Attorney for Applicant  
Registration No. 47,504  
Phone: 317-277-2620

Eli Lilly and Company  
Patent Division/GAC  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

Nov. 25, 2003